Ernexa Therapeutics (NASDAQ:ERNA) Issues Earnings Results

Ernexa Therapeutics (NASDAQ:ERNA) announced its quarterly earnings data on Friday. The company reported ($1.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.84) by $1.95, Zacks reports.

Ernexa Therapeutics Trading Up 2.2%

Shares of NASDAQ:ERNA traded up $0.04 during mid-day trading on Friday, reaching $1.87. The stock had a trading volume of 7,904 shares, compared to its average volume of 63,210. The company has a market cap of $3.05 million, a P/E ratio of -0.13 and a beta of 2.75. Ernexa Therapeutics has a 1 year low of $1.74 and a 1 year high of $46.11. The business’s 50 day moving average price is $3.01 and its 200 day moving average price is $6.91.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Thursday, October 15th. Wall Street Zen cut shares of Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $30.00.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.